Cheung, K. L., Evers, S. M. A. A., De Vries, H., Levy, P., Pokhrel, S., Jones, T., Danner, M., Wentlandt, J., Knufinke, L., Mayer, S. and Hiligsmann, M. (2018). Most important barriers and facilitators of HTA usage in decision-making in Europe. Expert Rev. Pharmacoecon. Outcomes Res., 18 (3). S. 297 - 305. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1744-8379

Full text not available from this repository.

Abstract

Background: To enhance usage of health technology assessment (HTA) in decision-making, it is important to prioritise important barriers and facilitators to the uptake of HTA. This study aims to quantify and compare the relative importance of barriers and facilitators regarding the use of HTA in several European countries.Methods: A survey containing two best-worst scaling (BWS) object case studies (i.e. barriers and facilitators) were conducted among 136 policy makers and HTA researchers from the Netherlands, Germany, France, and United Kingdom. Hierarchical Bayes analysis generated the mean relative importance score (RIS) for each factor and subgroup analyses assessed differences between countries.Results: Six barriers (RIS5) and five facilitators (RIS6) were deemed highly important. Eleven barriers and ten facilitators differed in their importance between countries. Policy characteristics, research & researcher characteristics, and organisation & resources were particularly important to facilitate uptake of HTA, such as an explicit framework for decision-making and research of sufficient quality.Conclusion: The most paramount barriers and facilitators to HTA usage were quantified. For all countries it is crucial to create an explicit framework for the decision-making context to include HTA evidence. Country differences in the quality of research emphasize the need for enhanced international collaboration in HTA.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Cheung, K. L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Evers, S. M. A. A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
De Vries, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Levy, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pokhrel, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jones, T.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Danner, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wentlandt, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Knufinke, L.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayer, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hiligsmann, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-200395
DOI: 10.1080/14737167.2018.1421459
Journal or Publication Title: Expert Rev. Pharmacoecon. Outcomes Res.
Volume: 18
Number: 3
Page Range: S. 297 - 305
Date: 2018
Publisher: TAYLOR & FRANCIS LTD
Place of Publication: ABINGDON
ISSN: 1744-8379
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
HEALTH TECHNOLOGY-ASSESSMENT; COST-EFFECTIVENESS ANALYSIS; ECONOMIC-EVALUATION; RESOURCE-ALLOCATION; CARE; WORST; ASSESSMENTS; COUNTRIES; IMPACTMultiple languages
Health Care Sciences & Services; Health Policy & Services; Pharmacology & PharmacyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/20039

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item